TOP HEADLINES

Featured Story

Louisiana Tech researchers use 3-D printing to create bioresorbable drug delivery system

Researchers at Louisiana Tech University say they have harnessed 3-D printing for drug delivery by fabricating bioresorbable filaments enabling targeted delivery of antibiotics or chemotherapeutics.

PharmaJet secures FDA approval for jet injection system for flu vaccine

The FDA has approved the first needle-free delivery system for the inactivated flu vaccine. The jet injector, made by Pennsylvania-based PharmaJet, has been shown to successfully provide vaccination without a needle jab, which could ultimately help improve vaccination rates.

Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition

Fresenius Kabi announced Aug. 26 that it has received approval of the Kabiven and Perikabiven, parenteral nutrition products in a three-chamber bag.

New antibody-drug conjugate research partnership announced

AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.

Russian scientists close in on drug-delivering nanorobots

Researchers at the Institute of General Physics at the Russian Academy of Sciences and the Moscow Institute of Physics and Technology said their advancement in biocomputing using nanoparticles is a step towards creating drug-delivering nanorobots.

 
MORE NEWS

From Our Sister Sites

FierceBiotech

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some high-profile attention for a batch of preliminary numbers suggesting a trend toward lower cardiovascular risks.

FierceBiotech

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely-watched therapy that has the potential to rival the most successful drug franchises now on the market.